Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Boehringer also highlighted its oral PDE4B inhibitor BI 1015550 for idiopathic pulmonary fibrosis, which has just picked up a breakthrough designation from the FDA after a positive phase 2 trial ...

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). The therapy was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February ...

Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn’s & Colitis ...

PDE4B Inhibitor, and JadiCells. The majority of medicines are still in the discovery and preclinical stages. JadiCells are being tested in a Phase I/II trial by Therapeutic Solutions International ...

Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn’s & Colitis ...

Palisade Bio presented a poster titled “PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model” at the Crohn’s & Colitis Congress ...